001     291763
005     20250814094432.0
024 7 _ |a 10.1016/j.ajcnut.2024.07.012
|2 doi
024 7 _ |a pmid:39025327
|2 pmid
024 7 _ |a 0095-9871
|2 ISSN
024 7 _ |a 0002-9165
|2 ISSN
024 7 _ |a 1938-3207
|2 ISSN
024 7 _ |a 1938-3215
|2 ISSN
024 7 _ |a altmetric:165450366
|2 altmetric
037 _ _ |a DKFZ-2024-01499
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Aglago, Elom K
|b 0
245 _ _ |a Folate intake and colorectal cancer risk according to genetic subtypes defined by targeted tumor sequencing.
260 _ _ |a Amsterdam
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726753819_11602
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Sep;120(3):664-673
520 _ _ |a Folate is involved in multiple genetic, epigenetic, and metabolic processes, and inadequate folate intake has been associated with an increased risk of cancer.We examined whether folate intake is differentially associated with colorectal cancer (CRC) risk according to somatic mutations in genes linked to CRC using targeted sequencing.Participants within two large CRC consortia with available information on dietary folate, supplemental folic acid, and total folate intake were included. Colorectal tumor samples from cases were sequenced for the presence of non-silent mutations in 105 genes and 6 signaling pathways (IGF2/PI3K, MMR, RTK/RAS, TGF-β, WNT, TP53/ATM). Multinomial logistic regression models were run comparing mutated/non-mutated CRC cases to controls to compute multivariable-adjusted odds ratios (ORs) with 95% confidence intervals (CI). Heterogeneity of associations of mutated versus non-mutated CRC cases was tested in case-only analyses using logistic regression. Analyses were performed separately in hypermutated and non-hypermutated tumors, as they exhibit different clinical behaviors.We included 4,339 CRC cases (702 hypermutated tumors, 16.2%) and 11,767 controls. Total folate intake was inversely associated with CRC risk (OR=0.93, 95%CI=0.90-0.96). Among hypermutated tumors, 12 genes (AXIN2, B2M, BCOR, CHD1, DOCK3, FBLN2, MAP3K21, POLD1, RYR1, TET2, UTP20, ZNF521) showed nominal statistical significance (P<0.05) for heterogeneity by mutation status, but none remained significant after multiple testing correction. Among these genetic subtypes, the associations between folate variables and CRC were mostly inverse or towards the null, except for tumors mutated for DOCK3 (supplemental folic acid), CHD1 (total folate), and ZNF521 (dietary folate) that showed positive associations. We did not observe differential associations in analyses among non-hypermutated tumors, or according to the signaling pathways.Folate intake was not differentially associated with CRC risk according to mutations in the genes explored. The nominally significant differential mutation effects observed in a few genes warrants further investigation.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a folate
|2 Other
650 _ 7 |a folic acid
|2 Other
650 _ 7 |a molecular subtypes
|2 Other
650 _ 7 |a somatic mutations
|2 Other
650 _ 7 |a tumor
|2 Other
700 1 _ |a Qu, Conghui
|b 1
700 1 _ |a Harlid, Sophia
|b 2
700 1 _ |a Phipps, Amanda I
|b 3
700 1 _ |a Steinfelder, Robert S
|b 4
700 1 _ |a Ogino, Shuji
|b 5
700 1 _ |a Thomas, Claire E
|b 6
700 1 _ |a Hsu, Li
|b 7
700 1 _ |a Toland, Amanda E
|b 8
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 9
|u dkfz
700 1 _ |a Berndt, Sonja I
|b 10
700 1 _ |a Buchanan, Daniel D
|b 11
700 1 _ |a Campbell, Peter T
|b 12
700 1 _ |a Cao, Yin
|b 13
700 1 _ |a Chan, Andrew T
|b 14
700 1 _ |a Drew, David A
|b 15
700 1 _ |a Figueiredo, Jane C
|b 16
700 1 _ |a French, Amy J
|b 17
700 1 _ |a Gallinger, Steven
|b 18
700 1 _ |a Georgeson, Peter
|b 19
700 1 _ |a Giannakis, Marios
|b 20
700 1 _ |a Goode, Ellen L
|b 21
700 1 _ |a Gruber, Stephen B
|b 22
700 1 _ |a Gunter, Marc J
|b 23
700 1 _ |a Harrison, Tabitha A
|b 24
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 25
|u dkfz
700 1 _ |a Huang, Wen-Yi
|b 26
700 1 _ |a Hullar, Meredith Aj
|b 27
700 1 _ |a Huyghe, Jeroen R
|b 28
700 1 _ |a Jenkins, Mark A
|b 29
700 1 _ |a Lynch, Brigid M
|b 30
700 1 _ |a Moreno, Victor
|b 31
700 1 _ |a Murphy, Neil
|b 32
700 1 _ |a Newton, Christina C
|b 33
700 1 _ |a Nowak, Jonathan A
|b 34
700 1 _ |a Obón-Santacana, Mireia
|b 35
700 1 _ |a Sun, Wei
|b 36
700 1 _ |a Ugai, Tomotaka
|b 37
700 1 _ |a Um, Caroline Y
|b 38
700 1 _ |a Zaidi, Syed H
|b 39
700 1 _ |a Tsilidis, Konstantinos K
|b 40
700 1 _ |a van Guelpen, Bethany
|b 41
700 1 _ |a Peters, Ulrike
|b 42
773 _ _ |a 10.1016/j.ajcnut.2024.07.012
|g p. S0002916524006099
|0 PERI:(DE-600)1496439-9
|n 3
|p 664-673
|t The American journal of clinical nutrition
|v 120
|y 2024
|x 0095-9871
856 4 _ |u https://inrepo02.dkfz.de/record/291763/files/1-s2.0-S0002916524006099-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291763/files/1-s2.0-S0002916524006099-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:291763
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J CLIN NUTR : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J CLIN NUTR : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21